Polymyalgia Rheumatica Treatment MarketPolymyalgia Rheumatica Treatment Market By Drug Class (Corticosteroids, Disease-Modifying Anti-Rheumatic Drugs (DMARDS), Nonsteroidal Anti-Inflammatory Drugs (NSAIDS), Others) By Route of Administration (Oral, Parenteral) By End-User (Hospitals , Specialty Clinics, Others) By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033

Published date: Dec 2023
Report ID: 77467
Number of Pages: 323
Format:

Fact Checked

Cite this Research

- 1. Executive Summary
  - 1.1. Definition
  - 1.2. Taxonomy
  - 1.3. Research Scope
  - 1.4. Key Analysis
  - 1.5. Key Findings by Major Segments
  - 1.6. Top strategies by Major Players
- 2. Global Polymyalgia Rheumatica Treatment Overview
  - 2.1. Polymyalgia Rheumatica Treatment Dynamics
    
    2.1.1. Drivers
    
    2.1.2. Opportunities
    
    2.1.2. Restraints
    
    2.1.4. Challenges
  - 2.2. Macro-economic Factors
  - 2.3. Regulatory Framework
  - 2.4. Market Investment Feasibility Index
  - 2.5. PEST Analysis
  - 2.6. PORTER’S Five Force Analysis
  - 2.7. Drivers & Restraints Impact Analysis
  - 2.8. Industry Chain Analysis
  - 2.9. Cost Structure Analysis
  - 2.10. Marketing Strategy
  - 2.11. Russia-Ukraine War Impact Analysis
  - 2.12. Opportunity Map Analysis
  - 2.13. Market Competition Scenario Analysis
  - 2.14. Product Life Cycle Analysis
  - 2.15. Opportunity Orbits
  - 2.16. Manufacturer Intensity Map
  - 2.17. Major Companies sales by Value & Volume
- 3. Global Polymyalgia Rheumatica Treatment Analysis, Opportunity and Forecast, 2016-2032
  - 3.1. Global Polymyalgia Rheumatica Treatment Analysis, 2016-2021
  - 3.2. Global Polymyalgia Rheumatica Treatment Opportunity and Forecast, 2023-2032
  - 3.3. Global Polymyalgia Rheumatica Treatment Analysis, Opportunity and Forecast, By Diagnostic Method, 2016-2032
    
    3.3.1. Global Polymyalgia Rheumatica Treatment Analysis by Diagnostic Method: Introduction
    
    3.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Diagnostic Method, 2016-2032
    
    3.3.3. Blood Tests
    
    3.3.4. Imaging Tests
  - 3.4. Global Polymyalgia Rheumatica Treatment Analysis, Opportunity and Forecast, By Drug Class, 2016-2032
    
    3.4.1. Global Polymyalgia Rheumatica Treatment Analysis by Drug Class: Introduction
    
    3.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Drug Class, 2016-2032
    
    3.4.3. Corticosteroids
    
    3.4.4. Disease-Modifying Anti-Rheumatic Drugs
    
    3.4.5. Non-Steroidal Anti-Inflammatory Drugs
  - 3.5. Global Polymyalgia Rheumatica Treatment Analysis, Opportunity and Forecast, By Route of Administration, 2016-2032
    
    3.5.1. Global Polymyalgia Rheumatica Treatment Analysis by Route of Administration: Introduction
    
    3.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Route of Administration, 2016-2032
    
    3.5.3. Oral
    
    3.5.4. Parenteral
  - 3.6. Global Polymyalgia Rheumatica Treatment Analysis, Opportunity and Forecast, By End-Use, 2016-2032
    
    3.6.1. Global Polymyalgia Rheumatica Treatment Analysis by End-Use: Introduction
    
    3.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, By End-Use, 2016-2032
    
    3.6.3. Hospitals
    
    3.6.4. Homecare
    
    3.6.5. Specialty Clinics
- 4. North America Polymyalgia Rheumatica Treatment Analysis, Opportunity and Forecast, 2016-2032
  - 4.1. North America Polymyalgia Rheumatica Treatment Analysis, 2016-2021
  - 4.2. North America Polymyalgia Rheumatica Treatment Opportunity and Forecast, 2023-2032
  - 4.3. North America Polymyalgia Rheumatica Treatment Analysis, Opportunity and Forecast, By Diagnostic Method, 2016-2032
    
    4.3.1. North America Polymyalgia Rheumatica Treatment Analysis by Diagnostic Method: Introduction
    
    4.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Diagnostic Method, 2016-2032
    
    4.3.3. Blood Tests
    
    4.3.4. Imaging Tests
  - 4.4. North America Polymyalgia Rheumatica Treatment Analysis, Opportunity and Forecast, By Drug Class, 2016-2032
    
    4.4.1. North America Polymyalgia Rheumatica Treatment Analysis by Drug Class: Introduction
    
    4.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Drug Class, 2016-2032
    
    4.4.3. Corticosteroids
    
    4.4.4. Disease-Modifying Anti-Rheumatic Drugs
    
    4.4.5. Non-Steroidal Anti-Inflammatory Drugs
  - 4.5. North America Polymyalgia Rheumatica Treatment Analysis, Opportunity and Forecast, By Route of Administration, 2016-2032
    
    4.5.1. North America Polymyalgia Rheumatica Treatment Analysis by Route of Administration: Introduction
    
    4.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Route of Administration, 2016-2032
    
    4.5.3. Oral
    
    4.5.4. Parenteral
  - 4.6. North America Polymyalgia Rheumatica Treatment Analysis, Opportunity and Forecast, By End-Use, 2016-2032
    
    4.6.1. North America Polymyalgia Rheumatica Treatment Analysis by End-Use: Introduction
    
    4.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, By End-Use, 2016-2032
    
    4.6.3. Hospitals
    
    4.6.4. Homecare
    
    4.6.5. Specialty Clinics
  - 4.7. North America Polymyalgia Rheumatica Treatment Analysis, Opportunity and Forecast, By Country , 2016-2032
    
    4.7.1. North America Polymyalgia Rheumatica Treatment Analysis by Country : Introduction
    
    4.7.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
    
    4.7.2.1. U.S.
    
    4.7.2.2. Canada
    
    4.7.2.3. Mexico
- 5. Europe Polymyalgia Rheumatica Treatment Analysis, Opportunity and Forecast, 2016-2032
  - 5.1. Europe Polymyalgia Rheumatica Treatment Analysis, 2016-2021
  - 5.2. Europe Polymyalgia Rheumatica Treatment Opportunity and Forecast, 2023-2032
  - 5.3. Europe Polymyalgia Rheumatica Treatment Analysis, Opportunity and Forecast, By Diagnostic Method, 2016-2032
    
    5.3.1. Europe Polymyalgia Rheumatica Treatment Analysis by Diagnostic Method: Introduction
    
    5.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Diagnostic Method, 2016-2032
    
    5.3.3. Blood Tests
    
    5.3.4. Imaging Tests
  - 5.4. Europe Polymyalgia Rheumatica Treatment Analysis, Opportunity and Forecast, By Drug Class, 2016-2032
    
    5.4.1. Europe Polymyalgia Rheumatica Treatment Analysis by Drug Class: Introduction
    
    5.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Drug Class, 2016-2032
    
    5.4.3. Corticosteroids
    
    5.4.4. Disease-Modifying Anti-Rheumatic Drugs
    
    5.4.5. Non-Steroidal Anti-Inflammatory Drugs
  - 5.5. Europe Polymyalgia Rheumatica Treatment Analysis, Opportunity and Forecast, By Route of Administration, 2016-2032
    
    5.5.1. Europe Polymyalgia Rheumatica Treatment Analysis by Route of Administration: Introduction
    
    5.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Route of Administration, 2016-2032
    
    5.5.3. Oral
    
    5.5.4. Parenteral
  - 5.6. Europe Polymyalgia Rheumatica Treatment Analysis, Opportunity and Forecast, By End-Use, 2016-2032
    
    5.6.1. Europe Polymyalgia Rheumatica Treatment Analysis by End-Use: Introduction
    
    5.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, By End-Use, 2016-2032
    
    5.6.3. Hospitals
    
    5.6.4. Homecare
    
    5.6.5. Specialty Clinics
  - 5.7. Europe Polymyalgia Rheumatica Treatment Analysis, Opportunity and Forecast, By Country , 2016-2032
    
    5.7.1. Europe Polymyalgia Rheumatica Treatment Analysis by Country : Introduction
    
    5.7.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
    
    5.7.2.1. U.K.
    
    5.7.2.2. Germany
    
    5.7.2.3. France
    
    5.7.2.4. Spain
    
    5.7.2.5. Italy
    
    5.7.2.6. Russia
    
    5.7.2.7. Rest of Europe
- 6. Asia-Pacific Polymyalgia Rheumatica Treatment Analysis, Opportunity and Forecast, 2016-2032
  - 6.1. Asia-Pacific Polymyalgia Rheumatica Treatment Analysis, 2016-2021
  - 6.2. Asia-Pacific Polymyalgia Rheumatica Treatment Opportunity and Forecast, 2023-2032
  - 6.3. Asia-Pacific Polymyalgia Rheumatica Treatment Analysis, Opportunity and Forecast, By Diagnostic Method, 2016-2032
    
    6.3.1. Asia-Pacific Polymyalgia Rheumatica Treatment Analysis by Diagnostic Method: Introduction
    
    6.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Diagnostic Method, 2016-2032
    
    6.3.3. Blood Tests
    
    6.3.4. Imaging Tests
  - 6.4. Asia-Pacific Polymyalgia Rheumatica Treatment Analysis, Opportunity and Forecast, By Drug Class, 2016-2032
    
    6.4.1. Asia-Pacific Polymyalgia Rheumatica Treatment Analysis by Drug Class: Introduction
    
    6.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Drug Class, 2016-2032
    
    6.4.3. Corticosteroids
    
    6.4.4. Disease-Modifying Anti-Rheumatic Drugs
    
    6.4.5. Non-Steroidal Anti-Inflammatory Drugs
  - 6.5. Asia-Pacific Polymyalgia Rheumatica Treatment Analysis, Opportunity and Forecast, By Route of Administration, 2016-2032
    
    6.5.1. Asia-Pacific Polymyalgia Rheumatica Treatment Analysis by Route of Administration: Introduction
    
    6.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Route of Administration, 2016-2032
    
    6.5.3. Oral
    
    6.5.4. Parenteral
  - 6.6. Asia-Pacific Polymyalgia Rheumatica Treatment Analysis, Opportunity and Forecast, By End-Use, 2016-2032
    
    6.6.1. Asia-Pacific Polymyalgia Rheumatica Treatment Analysis by End-Use: Introduction
    
    6.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, By End-Use, 2016-2032
    
    6.6.3. Hospitals
    
    6.6.4. Homecare
    
    6.6.5. Specialty Clinics
  - 6.7. Asia-Pacific Polymyalgia Rheumatica Treatment Analysis, Opportunity and Forecast, By Country , 2016-2032
    
    6.7.1. Asia-Pacific Polymyalgia Rheumatica Treatment Analysis by Country : Introduction
    
    6.7.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
    
    6.7.2.1. China
    
    6.7.2.2. Japan
    
    6.7.2.3. South Korea
    
    6.7.2.4. India
    
    6.7.2.5. Rest of Asia-Pacific
- 7. South America Polymyalgia Rheumatica Treatment Analysis, Opportunity and Forecast, 2016-2032
  - 7.1. South America Polymyalgia Rheumatica Treatment Analysis, 2016-2021
  - 7.2. South America Polymyalgia Rheumatica Treatment Opportunity and Forecast, 2023-2032
  - 7.3. South America Polymyalgia Rheumatica Treatment Analysis, Opportunity and Forecast, By Diagnostic Method, 2016-2032
    
    7.3.1. South America Polymyalgia Rheumatica Treatment Analysis by Diagnostic Method: Introduction
    
    7.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Diagnostic Method, 2016-2032
    
    7.3.3. Blood Tests
    
    7.3.4. Imaging Tests
  - 7.4. South America Polymyalgia Rheumatica Treatment Analysis, Opportunity and Forecast, By Drug Class, 2016-2032
    
    7.4.1. South America Polymyalgia Rheumatica Treatment Analysis by Drug Class: Introduction
    
    7.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Drug Class, 2016-2032
    
    7.4.3. Corticosteroids
    
    7.4.4. Disease-Modifying Anti-Rheumatic Drugs
    
    7.4.5. Non-Steroidal Anti-Inflammatory Drugs
  - 7.5. South America Polymyalgia Rheumatica Treatment Analysis, Opportunity and Forecast, By Route of Administration, 2016-2032
    
    7.5.1. South America Polymyalgia Rheumatica Treatment Analysis by Route of Administration: Introduction
    
    7.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Route of Administration, 2016-2032
    
    7.5.3. Oral
    
    7.5.4. Parenteral
  - 7.6. South America Polymyalgia Rheumatica Treatment Analysis, Opportunity and Forecast, By End-Use, 2016-2032
    
    7.6.1. South America Polymyalgia Rheumatica Treatment Analysis by End-Use: Introduction
    
    7.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, By End-Use, 2016-2032
    
    7.6.3. Hospitals
    
    7.6.4. Homecare
    
    7.6.5. Specialty Clinics
  - 7.7. South America Polymyalgia Rheumatica Treatment Analysis, Opportunity and Forecast, By Country , 2016-2032
    
    7.7.1. South America Polymyalgia Rheumatica Treatment Analysis by Country : Introduction
    
    7.7.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
    
    7.7.2.1. Brazil
    
    7.7.2.2. Argentina
    
    7.7.2.3. Rest of South America
- 8. Middle East and Africa Polymyalgia Rheumatica Treatment Analysis, Opportunity and Forecast, 2016-2032
  - 8.1. Middle East and Africa Polymyalgia Rheumatica Treatment Analysis, 2016-2021
  - 8.2. Middle East and Africa Polymyalgia Rheumatica Treatment Opportunity and Forecast, 2023-2032
  - 8.3. Middle East and Africa Polymyalgia Rheumatica Treatment Analysis, Opportunity and Forecast, By Diagnostic Method, 2016-2032
    
    8.3.1. Middle East and Africa Polymyalgia Rheumatica Treatment Analysis by Diagnostic Method: Introduction
    
    8.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Diagnostic Method, 2016-2032
    
    8.3.3. Blood Tests
    
    8.3.4. Imaging Tests
  - 8.4. Middle East and Africa Polymyalgia Rheumatica Treatment Analysis, Opportunity and Forecast, By Drug Class, 2016-2032
    
    8.4.1. Middle East and Africa Polymyalgia Rheumatica Treatment Analysis by Drug Class: Introduction
    
    8.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Drug Class, 2016-2032
    
    8.4.3. Corticosteroids
    
    8.4.4. Disease-Modifying Anti-Rheumatic Drugs
    
    8.4.5. Non-Steroidal Anti-Inflammatory Drugs
  - 8.5. Middle East and Africa Polymyalgia Rheumatica Treatment Analysis, Opportunity and Forecast, By Route of Administration, 2016-2032
    
    8.5.1. Middle East and Africa Polymyalgia Rheumatica Treatment Analysis by Route of Administration: Introduction
    
    8.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Route of Administration, 2016-2032
    
    8.5.3. Oral
    
    8.5.4. Parenteral
  - 8.6. Middle East and Africa Polymyalgia Rheumatica Treatment Analysis, Opportunity and Forecast, By End-Use, 2016-2032
    
    8.6.1. Middle East and Africa Polymyalgia Rheumatica Treatment Analysis by End-Use: Introduction
    
    8.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, By End-Use, 2016-2032
    
    8.6.3. Hospitals
    
    8.6.4. Homecare
    
    8.6.5. Specialty Clinics
  - 8.7. Middle East and Africa Polymyalgia Rheumatica Treatment Analysis, Opportunity and Forecast, By Country , 2016-2032
    
    8.7.1. Middle East and Africa Polymyalgia Rheumatica Treatment Analysis by Country : Introduction
    
    8.7.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
    
    8.7.2.1. GCC
    
    8.7.2.2. Israel
    
    8.7.2.3. South Africa
    
    8.7.2.4. Rest of MEA
- 9. Global Polymyalgia Rheumatica Treatment Analysis, Opportunity and Forecast, By Region , 2016-2032
  - 9.1. Global Polymyalgia Rheumatica Treatment Analysis by Region : Introduction
  - 9.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Region , 2016-2032
    
    9.2.1. North America
    
    9.2.2. Europe
    
    9.2.3. Asia-Pacific
    
    9.2.4. South America
    
    9.2.5. Middle East and Africa
- 10. Global Polymyalgia Rheumatica Treatment Competitive Landscape, Market Share Analysis, and Company Profiles
  - 10.1. Market Share Analysis
  - 10.2. Company Profiles
  - 10.3. Apotex Inc.
    
    10.3.1. Company Overview
    
    10.3.2. Financial Highlights
    
    10.3.3. Product Portfolio
    
    10.3.4. SWOT Analysis
    
    10.3.5. Key Strategies and Developments
  - 10.4. Teva Pharmaceutical Industries Ltd.
    
    10.4.1. Company Overview
    
    10.4.2. Financial Highlights
    
    10.4.3. Product Portfolio
    
    10.4.4. SWOT Analysis
    
    10.4.5. Key Strategies and Developments
  - 10.5. GlaxoSmithKline plc.
    
    10.5.1. Company Overview
    
    10.5.2. Financial Highlights
    
    10.5.3. Product Portfolio
    
    10.5.4. SWOT Analysis
    
    10.5.5. Key Strategies and Developments
  - 10.6. Mayo Foundation for Medical Education and Research (MFMER)
    
    10.6.1. Company Overview
    
    10.6.2. Financial Highlights
    
    10.6.3. Product Portfolio
    
    10.6.4. SWOT Analysis
    
    10.6.5. Key Strategies and Developments
  - 10.7. Cleveland Clinic
    
    10.7.1. Company Overview
    
    10.7.2. Financial Highlights
    
    10.7.3. Product Portfolio
    
    10.7.4. SWOT Analysis
    
    10.7.5. Key Strategies and Developments
  - 10.8. Arthritis Foundation
    
    10.8.1. Company Overview
    
    10.8.2. Financial Highlights
    
    10.8.3. Product Portfolio
    
    10.8.4. SWOT Analysis
    
    10.8.5. Key Strategies and Developments
  - 10.9. Healthily
    
    10.9.1. Company Overview
    
    10.9.2. Financial Highlights
    
    10.9.3. Product Portfolio
    
    10.9.4. SWOT Analysis
    
    10.9.5. Key Strategies and Developments
  - 10.10. Physio.co.uk
    
    10.10.1. Company Overview
    
    10.10.2. Financial Highlights
    
    10.10.3. Product Portfolio
    
    10.10.4. SWOT Analysis
    
    10.10.5. Key Strategies and Developments
  - 10.11. Sparrow Health Systems
    
    10.11.1. Company Overview
    
    10.11.2. Financial Highlights
    
    10.11.3. Product Portfolio
    
    10.11.4. SWOT Analysis
    
    10.11.5. Key Strategies and Developments
- 11. Assumptions and Acronyms
- 12. Research Methodology
- 13. Contact
"
- List of Figures
  - Figure 1: Global Polymyalgia Rheumatica Treatment Revenue (US$ Mn) Market Share by Diagnostic Method in 2022
  - Figure 2: Global Polymyalgia Rheumatica Treatment Market Attractiveness Analysis by Diagnostic Method, 2016-2032
  - Figure 3: Global Polymyalgia Rheumatica Treatment Revenue (US$ Mn) Market Share by Drug Classin 2022
  - Figure 4: Global Polymyalgia Rheumatica Treatment Market Attractiveness Analysis by Drug Class, 2016-2032
  - Figure 5: Global Polymyalgia Rheumatica Treatment Revenue (US$ Mn) Market Share by Route of Administrationin 2022
  - Figure 6: Global Polymyalgia Rheumatica Treatment Market Attractiveness Analysis by Route of Administration, 2016-2032
  - Figure 7: Global Polymyalgia Rheumatica Treatment Revenue (US$ Mn) Market Share by End-Usein 2022
  - Figure 8: Global Polymyalgia Rheumatica Treatment Market Attractiveness Analysis by End-Use, 2016-2032
  - Figure 9: Global Polymyalgia Rheumatica Treatment Revenue (US$ Mn) Market Share by Region in 2022
  - Figure 10: Global Polymyalgia Rheumatica Treatment Market Attractiveness Analysis by Region, 2016-2032
  - Figure 11: Global Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) (2016-2032)
  - Figure 12: Global Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by Region (2016-2032)
  - Figure 13: Global Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by Diagnostic Method (2016-2032)
  - Figure 14: Global Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by Drug Class (2016-2032)
  - Figure 15: Global Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by Route of Administration (2016-2032)
  - Figure 16: Global Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by End-Use (2016-2032)
  - Figure 17: Global Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by Region (2016-2032)
  - Figure 18: Global Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by Diagnostic Method (2016-2032)
  - Figure 19: Global Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by Drug Class (2016-2032)
  - Figure 20: Global Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by Route of Administration (2016-2032)
  - Figure 21: Global Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by End-Use (2016-2032)
  - Figure 22: Global Polymyalgia Rheumatica Treatment Market Share Comparison by Region (2016-2032)
  - Figure 23: Global Polymyalgia Rheumatica Treatment Market Share Comparison by Diagnostic Method (2016-2032)
  - Figure 24: Global Polymyalgia Rheumatica Treatment Market Share Comparison by Drug Class (2016-2032)
  - Figure 25: Global Polymyalgia Rheumatica Treatment Market Share Comparison by Route of Administration (2016-2032)
  - Figure 26: Global Polymyalgia Rheumatica Treatment Market Share Comparison by End-Use (2016-2032)
  - Figure 27: North America Polymyalgia Rheumatica Treatment Revenue (US$ Mn) Market Share by Diagnostic Methodin 2022
  - Figure 28: North America Polymyalgia Rheumatica Treatment Market Attractiveness Analysis by Diagnostic Method, 2016-2032
  - Figure 29: North America Polymyalgia Rheumatica Treatment Revenue (US$ Mn) Market Share by Drug Classin 2022
  - Figure 30: North America Polymyalgia Rheumatica Treatment Market Attractiveness Analysis by Drug Class, 2016-2032
  - Figure 31: North America Polymyalgia Rheumatica Treatment Revenue (US$ Mn) Market Share by Route of Administrationin 2022
  - Figure 32: North America Polymyalgia Rheumatica Treatment Market Attractiveness Analysis by Route of Administration, 2016-2032
  - Figure 33: North America Polymyalgia Rheumatica Treatment Revenue (US$ Mn) Market Share by End-Usein 2022
  - Figure 34: North America Polymyalgia Rheumatica Treatment Market Attractiveness Analysis by End-Use, 2016-2032
  - Figure 35: North America Polymyalgia Rheumatica Treatment Revenue (US$ Mn) Market Share by Country in 2022
  - Figure 36: North America Polymyalgia Rheumatica Treatment Market Attractiveness Analysis by Country, 2016-2032
  - Figure 37: North America Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) (2016-2032)
  - Figure 38: North America Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Figure 39: North America Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by Diagnostic Method (2016-2032)
  - Figure 40: North America Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by Drug Class (2016-2032)
  - Figure 41: North America Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by Route of Administration (2016-2032)
  - Figure 42: North America Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by End-Use (2016-2032)
  - Figure 43: North America Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
  - Figure 44: North America Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by Diagnostic Method (2016-2032)
  - Figure 45: North America Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by Drug Class (2016-2032)
  - Figure 46: North America Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by Route of Administration (2016-2032)
  - Figure 47: North America Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by End-Use (2016-2032)
  - Figure 48: North America Polymyalgia Rheumatica Treatment Market Share Comparison by Country (2016-2032)
  - Figure 49: North America Polymyalgia Rheumatica Treatment Market Share Comparison by Diagnostic Method (2016-2032)
  - Figure 50: North America Polymyalgia Rheumatica Treatment Market Share Comparison by Drug Class (2016-2032)
  - Figure 51: North America Polymyalgia Rheumatica Treatment Market Share Comparison by Route of Administration (2016-2032)
  - Figure 52: North America Polymyalgia Rheumatica Treatment Market Share Comparison by End-Use (2016-2032)
  - Figure 53: Europe Polymyalgia Rheumatica Treatment Revenue (US$ Mn) Market Share by Diagnostic Methodin 2022
  - Figure 54: Europe Polymyalgia Rheumatica Treatment Market Attractiveness Analysis by Diagnostic Method, 2016-2032
  - Figure 55: Europe Polymyalgia Rheumatica Treatment Revenue (US$ Mn) Market Share by Drug Classin 2022
  - Figure 56: Europe Polymyalgia Rheumatica Treatment Market Attractiveness Analysis by Drug Class, 2016-2032
  - Figure 57: Europe Polymyalgia Rheumatica Treatment Revenue (US$ Mn) Market Share by Route of Administrationin 2022
  - Figure 58: Europe Polymyalgia Rheumatica Treatment Market Attractiveness Analysis by Route of Administration, 2016-2032
  - Figure 59: Europe Polymyalgia Rheumatica Treatment Revenue (US$ Mn) Market Share by End-Usein 2022
  - Figure 60: Europe Polymyalgia Rheumatica Treatment Market Attractiveness Analysis by End-Use, 2016-2032
  - Figure 61: Europe Polymyalgia Rheumatica Treatment Revenue (US$ Mn) Market Share by Country in 2022
  - Figure 62: Europe Polymyalgia Rheumatica Treatment Market Attractiveness Analysis by Country, 2016-2032
  - Figure 63: Europe Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) (2016-2032)
  - Figure 64: Europe Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Figure 65: Europe Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by Diagnostic Method (2016-2032)
  - Figure 66: Europe Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by Drug Class (2016-2032)
  - Figure 67: Europe Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by Route of Administration (2016-2032)
  - Figure 68: Europe Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by End-Use (2016-2032)
  - Figure 69: Europe Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
  - Figure 70: Europe Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by Diagnostic Method (2016-2032)
  - Figure 71: Europe Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by Drug Class (2016-2032)
  - Figure 72: Europe Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by Route of Administration (2016-2032)
  - Figure 73: Europe Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by End-Use (2016-2032)
  - Figure 74: Europe Polymyalgia Rheumatica Treatment Market Share Comparison by Country (2016-2032)
  - Figure 75: Europe Polymyalgia Rheumatica Treatment Market Share Comparison by Diagnostic Method (2016-2032)
  - Figure 76: Europe Polymyalgia Rheumatica Treatment Market Share Comparison by Drug Class (2016-2032)
  - Figure 77: Europe Polymyalgia Rheumatica Treatment Market Share Comparison by Route of Administration (2016-2032)
  - Figure 78: Europe Polymyalgia Rheumatica Treatment Market Share Comparison by End-Use (2016-2032)
  - Figure 79: Asia-Pacific Polymyalgia Rheumatica Treatment Revenue (US$ Mn) Market Share by Diagnostic Methodin 2022
  - Figure 80: Asia-Pacific Polymyalgia Rheumatica Treatment Market Attractiveness Analysis by Diagnostic Method, 2016-2032
  - Figure 81: Asia-Pacific Polymyalgia Rheumatica Treatment Revenue (US$ Mn) Market Share by Drug Classin 2022
  - Figure 82: Asia-Pacific Polymyalgia Rheumatica Treatment Market Attractiveness Analysis by Drug Class, 2016-2032
  - Figure 83: Asia-Pacific Polymyalgia Rheumatica Treatment Revenue (US$ Mn) Market Share by Route of Administrationin 2022
  - Figure 84: Asia-Pacific Polymyalgia Rheumatica Treatment Market Attractiveness Analysis by Route of Administration, 2016-2032
  - Figure 85: Asia-Pacific Polymyalgia Rheumatica Treatment Revenue (US$ Mn) Market Share by End-Usein 2022
  - Figure 86: Asia-Pacific Polymyalgia Rheumatica Treatment Market Attractiveness Analysis by End-Use, 2016-2032
  - Figure 87: Asia-Pacific Polymyalgia Rheumatica Treatment Revenue (US$ Mn) Market Share by Country in 2022
  - Figure 88: Asia-Pacific Polymyalgia Rheumatica Treatment Market Attractiveness Analysis by Country, 2016-2032
  - Figure 89: Asia-Pacific Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) (2016-2032)
  - Figure 90: Asia-Pacific Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Figure 91: Asia-Pacific Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by Diagnostic Method (2016-2032)
  - Figure 92: Asia-Pacific Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by Drug Class (2016-2032)
  - Figure 93: Asia-Pacific Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by Route of Administration (2016-2032)
  - Figure 94: Asia-Pacific Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by End-Use (2016-2032)
  - Figure 95: Asia-Pacific Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
  - Figure 96: Asia-Pacific Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by Diagnostic Method (2016-2032)
  - Figure 97: Asia-Pacific Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by Drug Class (2016-2032)
  - Figure 98: Asia-Pacific Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by Route of Administration (2016-2032)
  - Figure 99: Asia-Pacific Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by End-Use (2016-2032)
  - Figure 100: Asia-Pacific Polymyalgia Rheumatica Treatment Market Share Comparison by Country (2016-2032)
  - Figure 101: Asia-Pacific Polymyalgia Rheumatica Treatment Market Share Comparison by Diagnostic Method (2016-2032)
  - Figure 102: Asia-Pacific Polymyalgia Rheumatica Treatment Market Share Comparison by Drug Class (2016-2032)
  - Figure 103: Asia-Pacific Polymyalgia Rheumatica Treatment Market Share Comparison by Route of Administration (2016-2032)
  - Figure 104: Asia-Pacific Polymyalgia Rheumatica Treatment Market Share Comparison by End-Use (2016-2032)
  - Figure 105: South America Polymyalgia Rheumatica Treatment Revenue (US$ Mn) Market Share by Diagnostic Methodin 2022
  - Figure 106: South America Polymyalgia Rheumatica Treatment Market Attractiveness Analysis by Diagnostic Method, 2016-2032
  - Figure 107: South America Polymyalgia Rheumatica Treatment Revenue (US$ Mn) Market Share by Drug Classin 2022
  - Figure 108: South America Polymyalgia Rheumatica Treatment Market Attractiveness Analysis by Drug Class, 2016-2032
  - Figure 109: South America Polymyalgia Rheumatica Treatment Revenue (US$ Mn) Market Share by Route of Administrationin 2022
  - Figure 110: South America Polymyalgia Rheumatica Treatment Market Attractiveness Analysis by Route of Administration, 2016-2032
  - Figure 111: South America Polymyalgia Rheumatica Treatment Revenue (US$ Mn) Market Share by End-Usein 2022
  - Figure 112: South America Polymyalgia Rheumatica Treatment Market Attractiveness Analysis by End-Use, 2016-2032
  - Figure 113: South America Polymyalgia Rheumatica Treatment Revenue (US$ Mn) Market Share by Country in 2022
  - Figure 114: South America Polymyalgia Rheumatica Treatment Market Attractiveness Analysis by Country, 2016-2032
  - Figure 115: South America Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) (2016-2032)
  - Figure 116: South America Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Figure 117: South America Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by Diagnostic Method (2016-2032)
  - Figure 118: South America Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by Drug Class (2016-2032)
  - Figure 119: South America Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by Route of Administration (2016-2032)
  - Figure 120: South America Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by End-Use (2016-2032)
  - Figure 121: South America Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
  - Figure 122: South America Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by Diagnostic Method (2016-2032)
  - Figure 123: South America Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by Drug Class (2016-2032)
  - Figure 124: South America Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by Route of Administration (2016-2032)
  - Figure 125: South America Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by End-Use (2016-2032)
  - Figure 126: South America Polymyalgia Rheumatica Treatment Market Share Comparison by Country (2016-2032)
  - Figure 127: South America Polymyalgia Rheumatica Treatment Market Share Comparison by Diagnostic Method (2016-2032)
  - Figure 128: South America Polymyalgia Rheumatica Treatment Market Share Comparison by Drug Class (2016-2032)
  - Figure 129: South America Polymyalgia Rheumatica Treatment Market Share Comparison by Route of Administration (2016-2032)
  - Figure 130: South America Polymyalgia Rheumatica Treatment Market Share Comparison by End-Use (2016-2032)
  - Figure 131: Middle East and Africa Polymyalgia Rheumatica Treatment Revenue (US$ Mn) Market Share by Diagnostic Methodin 2022
  - Figure 132: Middle East and Africa Polymyalgia Rheumatica Treatment Market Attractiveness Analysis by Diagnostic Method, 2016-2032
  - Figure 133: Middle East and Africa Polymyalgia Rheumatica Treatment Revenue (US$ Mn) Market Share by Drug Classin 2022
  - Figure 134: Middle East and Africa Polymyalgia Rheumatica Treatment Market Attractiveness Analysis by Drug Class, 2016-2032
  - Figure 135: Middle East and Africa Polymyalgia Rheumatica Treatment Revenue (US$ Mn) Market Share by Route of Administrationin 2022
  - Figure 136: Middle East and Africa Polymyalgia Rheumatica Treatment Market Attractiveness Analysis by Route of Administration, 2016-2032
  - Figure 137: Middle East and Africa Polymyalgia Rheumatica Treatment Revenue (US$ Mn) Market Share by End-Usein 2022
  - Figure 138: Middle East and Africa Polymyalgia Rheumatica Treatment Market Attractiveness Analysis by End-Use, 2016-2032
  - Figure 139: Middle East and Africa Polymyalgia Rheumatica Treatment Revenue (US$ Mn) Market Share by Country in 2022
  - Figure 140: Middle East and Africa Polymyalgia Rheumatica Treatment Market Attractiveness Analysis by Country, 2016-2032
  - Figure 141: Middle East and Africa Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) (2016-2032)
  - Figure 142: Middle East and Africa Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Figure 143: Middle East and Africa Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by Diagnostic Method (2016-2032)
  - Figure 144: Middle East and Africa Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by Drug Class (2016-2032)
  - Figure 145: Middle East and Africa Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by Route of Administration (2016-2032)
  - Figure 146: Middle East and Africa Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by End-Use (2016-2032)
  - Figure 147: Middle East and Africa Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
  - Figure 148: Middle East and Africa Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by Diagnostic Method (2016-2032)
  - Figure 149: Middle East and Africa Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by Drug Class (2016-2032)
  - Figure 150: Middle East and Africa Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by Route of Administration (2016-2032)
  - Figure 151: Middle East and Africa Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by End-Use (2016-2032)
  - Figure 152: Middle East and Africa Polymyalgia Rheumatica Treatment Market Share Comparison by Country (2016-2032)
  - Figure 153: Middle East and Africa Polymyalgia Rheumatica Treatment Market Share Comparison by Diagnostic Method (2016-2032)
  - Figure 154: Middle East and Africa Polymyalgia Rheumatica Treatment Market Share Comparison by Drug Class (2016-2032)
  - Figure 155: Middle East and Africa Polymyalgia Rheumatica Treatment Market Share Comparison by Route of Administration (2016-2032)
  - Figure 156: Middle East and Africa Polymyalgia Rheumatica Treatment Market Share Comparison by End-Use (2016-2032)
  "
- List of Tables
  - Table 1: Global Polymyalgia Rheumatica Treatment Market Comparison by Diagnostic Method (2016-2032)
  - Table 2: Global Polymyalgia Rheumatica Treatment Market Comparison by Drug Class (2016-2032)
  - Table 3: Global Polymyalgia Rheumatica Treatment Market Comparison by Route of Administration (2016-2032)
  - Table 4: Global Polymyalgia Rheumatica Treatment Market Comparison by End-Use (2016-2032)
  - Table 5: Global Polymyalgia Rheumatica Treatment Revenue (US$ Mn) Comparison by Region (2016-2032)
  - Table 6: Global Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) (2016-2032)
  - Table 7: Global Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by Region (2016-2032)
  - Table 8: Global Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by Diagnostic Method (2016-2032)
  - Table 9: Global Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by Drug Class (2016-2032)
  - Table 10: Global Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by Route of Administration (2016-2032)
  - Table 11: Global Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by End-Use (2016-2032)
  - Table 12: Global Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by Region (2016-2032)
  - Table 13: Global Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by Diagnostic Method (2016-2032)
  - Table 14: Global Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by Drug Class (2016-2032)
  - Table 15: Global Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by Route of Administration (2016-2032)
  - Table 16: Global Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by End-Use (2016-2032)
  - Table 17: Global Polymyalgia Rheumatica Treatment Market Share Comparison by Region (2016-2032)
  - Table 18: Global Polymyalgia Rheumatica Treatment Market Share Comparison by Diagnostic Method (2016-2032)
  - Table 19: Global Polymyalgia Rheumatica Treatment Market Share Comparison by Drug Class (2016-2032)
  - Table 20: Global Polymyalgia Rheumatica Treatment Market Share Comparison by Route of Administration (2016-2032)
  - Table 21: Global Polymyalgia Rheumatica Treatment Market Share Comparison by End-Use (2016-2032)
  - Table 22: North America Polymyalgia Rheumatica Treatment Market Comparison by Drug Class (2016-2032)
  - Table 23: North America Polymyalgia Rheumatica Treatment Market Comparison by Route of Administration (2016-2032)
  - Table 24: North America Polymyalgia Rheumatica Treatment Market Comparison by End-Use (2016-2032)
  - Table 25: North America Polymyalgia Rheumatica Treatment Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Table 26: North America Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) (2016-2032)
  - Table 27: North America Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Table 28: North America Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by Diagnostic Method (2016-2032)
  - Table 29: North America Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by Drug Class (2016-2032)
  - Table 30: North America Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by Route of Administration (2016-2032)
  - Table 31: North America Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by End-Use (2016-2032)
  - Table 32: North America Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
  - Table 33: North America Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by Diagnostic Method (2016-2032)
  - Table 34: North America Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by Drug Class (2016-2032)
  - Table 35: North America Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by Route of Administration (2016-2032)
  - Table 36: North America Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by End-Use (2016-2032)
  - Table 37: North America Polymyalgia Rheumatica Treatment Market Share Comparison by Country (2016-2032)
  - Table 38: North America Polymyalgia Rheumatica Treatment Market Share Comparison by Diagnostic Method (2016-2032)
  - Table 39: North America Polymyalgia Rheumatica Treatment Market Share Comparison by Drug Class (2016-2032)
  - Table 40: North America Polymyalgia Rheumatica Treatment Market Share Comparison by Route of Administration (2016-2032)
  - Table 41: North America Polymyalgia Rheumatica Treatment Market Share Comparison by End-Use (2016-2032)
  - Table 42: Europe Polymyalgia Rheumatica Treatment Market Comparison by Diagnostic Method (2016-2032)
  - Table 43: Europe Polymyalgia Rheumatica Treatment Market Comparison by Drug Class (2016-2032)
  - Table 44: Europe Polymyalgia Rheumatica Treatment Market Comparison by Route of Administration (2016-2032)
  - Table 45: Europe Polymyalgia Rheumatica Treatment Market Comparison by End-Use (2016-2032)
  - Table 46: Europe Polymyalgia Rheumatica Treatment Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Table 47: Europe Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) (2016-2032)
  - Table 48: Europe Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Table 49: Europe Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by Diagnostic Method (2016-2032)
  - Table 50: Europe Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by Drug Class (2016-2032)
  - Table 51: Europe Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by Route of Administration (2016-2032)
  - Table 52: Europe Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by End-Use (2016-2032)
  - Table 53: Europe Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
  - Table 54: Europe Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by Diagnostic Method (2016-2032)
  - Table 55: Europe Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by Drug Class (2016-2032)
  - Table 56: Europe Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by Route of Administration (2016-2032)
  - Table 57: Europe Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by End-Use (2016-2032)
  - Table 58: Europe Polymyalgia Rheumatica Treatment Market Share Comparison by Country (2016-2032)
  - Table 59: Europe Polymyalgia Rheumatica Treatment Market Share Comparison by Diagnostic Method (2016-2032)
  - Table 60: Europe Polymyalgia Rheumatica Treatment Market Share Comparison by Drug Class (2016-2032)
  - Table 61: Europe Polymyalgia Rheumatica Treatment Market Share Comparison by Route of Administration (2016-2032)
  - Table 62: Europe Polymyalgia Rheumatica Treatment Market Share Comparison by End-Use (2016-2032)
  - Table 63: Asia-Pacific Polymyalgia Rheumatica Treatment Market Comparison by Diagnostic Method (2016-2032)
  - Table 64: Asia-Pacific Polymyalgia Rheumatica Treatment Market Comparison by Drug Class (2016-2032)
  - Table 65: Asia-Pacific Polymyalgia Rheumatica Treatment Market Comparison by Route of Administration (2016-2032)
  - Table 66: Asia-Pacific Polymyalgia Rheumatica Treatment Market Comparison by End-Use (2016-2032)
  - Table 67: Asia-Pacific Polymyalgia Rheumatica Treatment Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Table 68: Asia-Pacific Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) (2016-2032)
  - Table 69: Asia-Pacific Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Table 70: Asia-Pacific Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by Diagnostic Method (2016-2032)
  - Table 71: Asia-Pacific Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by Drug Class (2016-2032)
  - Table 72: Asia-Pacific Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by Route of Administration (2016-2032)
  - Table 73: Asia-Pacific Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by End-Use (2016-2032)
  - Table 74: Asia-Pacific Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
  - Table 75: Asia-Pacific Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by Diagnostic Method (2016-2032)
  - Table 76: Asia-Pacific Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by Drug Class (2016-2032)
  - Table 77: Asia-Pacific Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by Route of Administration (2016-2032)
  - Table 78: Asia-Pacific Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by End-Use (2016-2032)
  - Table 79: Asia-Pacific Polymyalgia Rheumatica Treatment Market Share Comparison by Country (2016-2032)
  - Table 80: Asia-Pacific Polymyalgia Rheumatica Treatment Market Share Comparison by Diagnostic Method (2016-2032)
  - Table 81: Asia-Pacific Polymyalgia Rheumatica Treatment Market Share Comparison by Drug Class (2016-2032)
  - Table 82: Asia-Pacific Polymyalgia Rheumatica Treatment Market Share Comparison by Route of Administration (2016-2032)
  - Table 83: Asia-Pacific Polymyalgia Rheumatica Treatment Market Share Comparison by End-Use (2016-2032)
  - Table 84: South America Polymyalgia Rheumatica Treatment Market Comparison by Diagnostic Method (2016-2032)
  - Table 85: South America Polymyalgia Rheumatica Treatment Market Comparison by Drug Class (2016-2032)
  - Table 86: South America Polymyalgia Rheumatica Treatment Market Comparison by Route of Administration (2016-2032)
  - Table 87: South America Polymyalgia Rheumatica Treatment Market Comparison by End-Use (2016-2032)
  - Table 88: South America Polymyalgia Rheumatica Treatment Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Table 89: South America Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) (2016-2032)
  - Table 90: South America Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Table 91: South America Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by Diagnostic Method (2016-2032)
  - Table 92: South America Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by Drug Class (2016-2032)
  - Table 93: South America Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by Route of Administration (2016-2032)
  - Table 94: South America Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by End-Use (2016-2032)
  - Table 95: South America Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
  - Table 96: South America Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by Diagnostic Method (2016-2032)
  - Table 97: South America Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by Drug Class (2016-2032)
  - Table 98: South America Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by Route of Administration (2016-2032)
  - Table 99: South America Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by End-Use (2016-2032)
  - Table 100: South America Polymyalgia Rheumatica Treatment Market Share Comparison by Country (2016-2032)
  - Table 101: South America Polymyalgia Rheumatica Treatment Market Share Comparison by Diagnostic Method (2016-2032)
  - Table 102: South America Polymyalgia Rheumatica Treatment Market Share Comparison by Drug Class (2016-2032)
  - Table 103: South America Polymyalgia Rheumatica Treatment Market Share Comparison by Route of Administration (2016-2032)
  - Table 104: South America Polymyalgia Rheumatica Treatment Market Share Comparison by End-Use (2016-2032)
  - Table 105: Middle East and Africa Polymyalgia Rheumatica Treatment Market Comparison by Diagnostic Method (2016-2032)
  - Table 106: Middle East and Africa Polymyalgia Rheumatica Treatment Market Comparison by Drug Class (2016-2032)
  - Table 107: Middle East and Africa Polymyalgia Rheumatica Treatment Market Comparison by Route of Administration (2016-2032)
  - Table 108: Middle East and Africa Polymyalgia Rheumatica Treatment Market Comparison by End-Use (2016-2032)
  - Table 109: Middle East and Africa Polymyalgia Rheumatica Treatment Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Table 110: Middle East and Africa Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) (2016-2032)
  - Table 111: Middle East and Africa Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Table 112: Middle East and Africa Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by Diagnostic Method (2016-2032)
  - Table 113: Middle East and Africa Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by Drug Class (2016-2032)
  - Table 114: Middle East and Africa Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by Route of Administration (2016-2032)
  - Table 115: Middle East and Africa Polymyalgia Rheumatica Treatment Market Revenue (US$ Mn) Comparison by End-Use (2016-2032)
  - Table 116: Middle East and Africa Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
  - Table 117: Middle East and Africa Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by Diagnostic Method (2016-2032)
  - Table 118: Middle East and Africa Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by Drug Class (2016-2032)
  - Table 119: Middle East and Africa Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by Route of Administration (2016-2032)
  - Table 120: Middle East and Africa Polymyalgia Rheumatica Treatment Market Y-o-Y Growth Rate Comparison by End-Use (2016-2032)
  - Table 121: Middle East and Africa Polymyalgia Rheumatica Treatment Market Share Comparison by Country (2016-2032)
  - Table 122: Middle East and Africa Polymyalgia Rheumatica Treatment Market Share Comparison by Diagnostic Method (2016-2032)
  - Table 123: Middle East and Africa Polymyalgia Rheumatica Treatment Market Share Comparison by Drug Class (2016-2032)
  - Table 124: Middle East and Africa Polymyalgia Rheumatica Treatment Market Share Comparison by Route of Administration (2016-2032)
  - Table 125: Middle East and Africa Polymyalgia Rheumatica Treatment Market Share Comparison by End-Use (2016-2032)
- Regeneron Pharmaceuticals Inc.
- Sanofi
- GSK plc
- Merck & Co., Inc.
- Pfizer Inc.
- Centurion Healthcare Private Limited
- Hovione
- MODASA, Pharmaceuticals Pvt. Ltd.
- F. Hoffmann-La Roche Ltd.
- AbbVie Inc.